Viela Bio Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Viela Bio's estimated annual revenue is currently $1.4M per year.(i)
  • Viela Bio received $250.0M in venture funding in March 2018.
  • Viela Bio's estimated revenue per employee is $77,500
  • Viela Bio's total funding is $357.3M.

Employee Data

  • Viela Bio has 18 Employees.(i)
  • Viela Bio grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company's portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland. Learn more at



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Viela Bio News

2022-04-06 - Neuromyelitis Optics Therapy Market is expected to witness ...

... to witness significant growth over the forecast by 2028 | Alexion Pharmaceuticals Inc., Chugai Pharmaceutical Co., Ltd., Viela Bio, Inc.

2022-04-06 - Movers & Shakers, April 8 | BioSpace

... recently was vice president of clinical development at Horizon Therapeutics following its acquisition of Viela Bio, Inc. Prior to that,...

2022-03-30 - eGenesis Appoints Eliezer Katz, MD, FACS, as Chief Medical ...

Most recently, he was Vice President, Clinical Development at Horizon Therapeutics following its acquisition of Viela Bio, Inc. At Horizon...

2019-09-07 - 5 things to know ahead of Viela Bio’s planned $150M IPO

It's a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Viela Bio Funding

DateAmountRoundLead InvestorsReference
2018-03-01$250.0MUndisclosedBoyu CapitalArticle